U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C17H19N3O3S
Molecular Weight 345.4178
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of OMEPRAZOLE

SMILES

Cc1cnc(CS(=O)c2nc3ccc(cc3[nH]2)OC)c(C)c1OC

InChI

InChIKey=SUBDBMMJDZJVOS-UHFFFAOYSA-N
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)

HIDE SMILES / InChI

Molecular Formula C17H19N3O3S
Molecular Weight 345.4178
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Omeprazole belongs to a class of antisecretory compounds, which suppress gastric acid secretion by specific inhibition of the H+ /K+ ATPase enzyme system at the secretory surface of the gastric parietal cell. Because this enzyme system is regarded as the acid (proton) pump within the gastric mucosa, omeprazole has been characterized as a gastric acid-pump inhibitor, in that it blocks the final step of acid production. This effect is dose-related and leads to inhibition of both basal and stimulated acid secretion irrespective of the stimulus. Omeprazole is used under brand names Prilosec and Losec for treatment of duodenal ulcer in adults, gastric ulcer in adults, Gastroesophageal Reflux Disease. In addition it used for maintenance of healing of erosive esophagitis in pediatric patients and adults and for treatment of pathological hypersecretory conditions in adults (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis). The most frequent significant adverse effects occurring in at least of patients include headache; upper respiratory tract infection, abdominal pain, diarrhea, back pain, weakness and rash.

CNS Activity

Curator's Comment:: Known to be CNS penetrant in mouse. Human data not available

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
NEXIUM 24HR

Approved Use

treats frequent heartburn (occurs 2 or more days a week)

Launch Date

1395878400000
Primary
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

1205971200000
Primary
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

1205971200000
Primary
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

621734400000
Primary
PRILOSEC

Approved Use

PRILOSEC is a proton pump inhibitor indicated for: treatment of duodenal ulcer in adults, treatment of gastric ulcer in adults. Treatment of Gastroesophageal Reflux Disease. Maintenance of healing of erosive esophagitis in pediatric patients and adults. Treatment of pathological hypersecretory conditions in adults.

Launch Date

1205971200000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
7.5 μM
40 mg 1 times / day multiple, intravenous
dose: 40 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ESOMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
668 ng/mL
1 mg/kg single, oral
dose: 1 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
16.2 μM × h
40 mg 1 times / day multiple, intravenous
dose: 40 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ESOMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1220 ng × h/mL
1 mg/kg single, oral
dose: 1 mg/kg
route of administration: Oral
experiment type: SINGLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1179 nM × h
20 mg 1 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
1200 nM*h
20 mg single, oral
dose: 20 mg
route of administration: oral
experiment type: single
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: healthy
age: adults
sex:
food status:
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.4 h
40 mg 1 times / day multiple, intravenous
dose: 40 mg
route of administration: Intravenous
experiment type: MULTIPLE
co-administered:
ESOMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.58 h
20 mg 1 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
OMEPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 45.2
Health Status: unhealthy
Age Group: 45.2
Sex: M+F
Sources:
Other AEs: Nausea, Diarrhoea...
Other AEs:
Nausea (7%)
Diarrhoea (6%)
Headache (3%)
Sources:
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Other AEs: Headache, Abdominal pain...
Other AEs:
Headache (6.9%)
Abdominal pain (5.2%)
Nausea (4%)
Diarrhea (3.7%)
Vomiting (3.2%)
Flatulence (2.7%)
Esophageal acid reflux (1.9%)
Upper respiratory infection (1.9%)
Constipation (1.5%)
Dizziness (1.5%)
Rash (1.5%)
Asthenia (1.3%)
Back pain (1.1%)
Cough (1.1%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Headache 3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 45.2
Health Status: unhealthy
Age Group: 45.2
Sex: M+F
Sources:
Diarrhoea 6%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 45.2
Health Status: unhealthy
Age Group: 45.2
Sex: M+F
Sources:
Nausea 7%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy, 45.2
Health Status: unhealthy
Age Group: 45.2
Sex: M+F
Sources:
Back pain 1.1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Cough 1.1%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Asthenia 1.3%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Constipation 1.5%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Dizziness 1.5%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Rash 1.5%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Esophageal acid reflux 1.9%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Upper respiratory infection 1.9%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Flatulence 2.7%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Vomiting 3.2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Diarrhea 3.7%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Nausea 4%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Abdominal pain 5.2%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
Headache 6.9%
20 mg 1 times / day multiple, oral
Recommended
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources:
unhealthy
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
strong [IC50 3.7 uM]
yes (co-administration study)
Comment: Esomeprazole administration resulted in a significant increase (1.67‐fold) in the AUC0–∞ of proguanil and a significant decrease (0.522‐fold) in that of cycloguanil
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [IC50 >40 uM]
weak [Ki 150 uM]
weak (co-administration study)
Comment: Omeprazole exerts a concentration-dependent inhibition of CYP1A2 activity in man. However, even after single oral doses up to 80 mg, this effect is weak and without clinical relevance
weak [Ki 367.5 uM]
weak [Ki 745.1 uM]
yes [IC50 1.2 uM]
likely (co-administration study)
Comment: The frequency of delayed MTX elimination in patients administered esomeprazole was 71.4%
yes [IC50 15.7 uM]
yes [IC50 17.6 uM]
yes [IC50 17.7 uM]
yes [IC50 22 uM]
yes [IC50 4.32 uM]
yes [IC50 6.7 uM]
yes [IC50 6.8 uM]
yes [IC50 84.3 uM]
unlikely (co-administration study)
Comment: Coaministration with simvastatin acid unlikely results in DDIs
yes [Ki 7.1 uM]
yes (co-administration study)
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes (expression study)
Comment: livers of patients treated with omeprazole showed higher MRP3 protein expression
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: When voriconazole was given with omeprazole to healthy subjects, it significantly increased the steady-state Cmax and AUC0-24 of omeprazole, an average of 2 times and 4 times, respectively
major
yes (co-administration study)
Comment: Drugs known to induce CYP2C19 or CYP3A4 (such as rifampin) may lead to decreased omeprazole serum levels. In a cross-over study in 12 healthy male subjects, St John’s wort, an inducer of CYP3A4, decreased the systemic exposure of omeprazole in CYP2C19 poor metabolisers (Cmax and AUC decreased by 37.5% and 37.9%, respectively) and extensive metabolisers (Cmax and AUC decreased by 49.6% and 43.9%, respectively)
minor
minor
minor
no
yes
yes (co-administration study)
Comment: Drugs which induce CYP2C19 or CYP3A4 (such as St. John’s Wort or rifampin) can substantially decrease esomeprazole concentrations
yes
yes (pharmacogenomic study)
Comment: Drugs which induce CYP2C19 or CYP3A4 (such as St. John’s Wort or rifampin) can substantially decrease esomeprazole concentrations; The CYP2C19 isoenzyme exhibits polymorphism in the metabolism of esomeprazole, since some 3% of Caucasians and 15–20% of Asians lack CYP2C19 and are termed poor metabolizers. At steady state, the ratio of AUC in poor metabolizers to AUC in the rest of the population (normal metabolizers) is approximately 2
PubMed

PubMed

TitleDatePubMed
Measurement of cytochrome P450 gene induction in human hepatocytes using quantitative real-time reverse transcriptase-polymerase chain reaction.
2000 Jul
Pharmacokinetic study of esomeprazole in the elderly.
2001
Effect of Lactobacillus GG supplementation on antibiotic-associated gastrointestinal side effects during Helicobacter pylori eradication therapy: a pilot study.
2001
Antireflux surgery in children suffering from reflux-associated respiratory disease?
2001 Apr
Effect of the treatment of Helicobacter pylori infection on gastric emptying and its influence on the glycaemic control in type 1 diabetes mellitus.
2001 Apr
Improved high performance liquid chromatographic analysis of omeprazole in human plasma.
2001 Feb
Gastroesophageal reflux disease and Barrett's esophagus.
2001 Feb
Increased acid and bile reflux in Barrett's esophagus compared to reflux esophagitis, and effect of proton pump inhibitor therapy.
2001 Feb
[Usefulness of new triple therapy containing PPI].
2001 Feb
[Selection of antibiotics and planning of eradication for H. pylori infection].
2001 Feb
Pharmacodynamic modeling of pantoprazole's irreversible effect on gastric acid secretion in humans and rats.
2001 Feb
Antibiotic-resistance patterns of Helicobacter pylori in Croatia: cohort study.
2001 Feb
CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.
2001 Feb
The prescribing of acid suppressants prior to the endoscopic diagnosis of Barrett's oesophagus and oesophagitis.
2001 Feb
Analysis of gastrin receptor gene expression in proliferating cells in the neck zone of gastric fundic glands using laser capture microdissection.
2001 Feb 2
Management of GERD: medical versus surgical.
2001 Jan
Allergic contact dermatitis due to lansoprazole, a proton pump inhibitor.
2001 Jan
Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
2001 Jan
[Ulcer therapy with a new proton pump inhibitor. One week of treatment is enough].
2001 Jan 11
Hypergastrinemia promotes adenoma progression in the APC(Min-/+) mouse model of familial adenomatous polyposis.
2001 Jan 15
Biochemical properties of a newly synthesized H(+)/K(+) ATPase inhibitor, 1-(2-methyl-4-methoxyphenyl)-4-.
2001 Jan 5
Current approaches to reducing gastrointestinal toxicity of low-dose aspirin.
2001 Jan 8
Clinical onset of the Crohn's disease after eradication therapy of Helicobacter pylori infection. Does Helicobacter pylori infection interact with natural history of inflammatory bowel diseases?
2001 Jan-Feb
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
2001 Mar
Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial.
2001 Mar
Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs.
2001 Mar
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.
2001 Mar
Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of 'on-demand' therapy for 6 months.
2001 Mar
Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment.
2001 Mar
Improvement in atrophic gastritis and intestinal metaplasia in patients in whom Helicobacter pylori was eradicated.
2001 Mar 6
New OTC drugs and devices 2000: a selective review.
2001 Mar-Apr
Microsatellite instability at D18S61 is associated with no regression of gastric mucosa-associated lymphoid tissue lymphoma after Helicobacter pylori eradication.
2001 Mar-Apr
Patents

Sample Use Guides

The drug is administered orally, once daily. The dose depends on the condition treated.
Route of Administration: Oral
Pretreatment of omeprazole (10-6 - 10-4M) dose-dependently inhibits neutrophil adherence and respiratory burst induced by H. pylori. These evidences imply that omeprazole may exhibit a beneficial effect on H. pylori-associated gastric mucosal damage caused by activated neutrophils.
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:00:46 UTC 2021
Edited
by admin
on Fri Jun 25 21:00:46 UTC 2021
Record UNII
KG60484QX9
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
OMEPRAZOLE
EP   GREEN BOOK   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
OMEPRAZOLE [JAN]
Common Name English
OMEPRAZOLE COMPONENT OF ZEGERID
Common Name English
5-METHOXY-2-(((4-METHOXY-3,5,-DIMETHYL-2-PYRIDINYL)-METHYL)SULPHINYL)-1H-BENZIMIDAZOLE
Common Name English
NSC-759192
Code English
NSC-751450
Code English
1H-BENZIMIDAZOLE, 5-METHOXY-2-(((4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL)SULFINYL)-
Systematic Name English
OMEPRAZOLE COMPONENT OF YOSPRALA
Brand Name English
OMEPRAZOLE [USP]
Common Name English
OMEPRAZOLE [USP-RS]
Common Name English
OMEPRAZOLE [USP MONOGRAPH]
Common Name English
OMEPRAZOLE [HSDB]
Common Name English
OMEPRAZOLE [MART.]
Common Name English
LOSEC
Brand Name English
H-168/68
Code English
5-METHOXY-2-(((4-METHOXY-3,5-DIMETHYL-2-PYRIDYL)METHYL)SULFINYL)BENZIMIDAZOLE
Systematic Name English
OMEPRAZOLE [MI]
Common Name English
OMEPRAZOLE [GREEN BOOK]
Common Name English
ZEGERID COMPONENT OMEPRAZOLE
Common Name English
OMEPRAZOLE [WHO-DD]
Common Name English
(RS)-6-METHOXY-2-((4-METHOXY-3,5-DIMETHYLPYRIDIN-2-YL) METHYLSULFINYL)-1H-BENZO(D)IMIDAZOLE
Systematic Name English
OMEPRAZOLE [INN]
Common Name English
H 168/68
Code English
OMEPRAZOLE [VANDF]
Common Name English
OMEPRAZOLE [ORANGE BOOK]
Common Name English
OMEPRAZOLE [USAN]
Common Name English
YOSPRALA COMPONENT OMEPRAZOLE
Brand Name English
Classification Tree Code System Code
WHO-ATC A02BD05
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
WHO-VATC QA02BD01
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
WHO-ATC A02BC01
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
WHO-VATC QA02BD05
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
CFR 21 CFR 520.1615
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
LIVERTOX 710
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
NDF-RT N0000175525
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
FDA ORPHAN DRUG 446014
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
WHO-ATC A02BD01
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
WHO-VATC QA02BC01
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
NCI_THESAURUS C29723
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
WHO-ESSENTIAL MEDICINES LIST 17.1
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
NDF-RT N0000000147
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
Code System Code Type Description
MERCK INDEX
M8209
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY Merck Index
MESH
D009853
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
RXCUI
7646
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C716
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
NDF-RT
N0000182140
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY Cytochrome P450 2C19 Inhibitors [MoA]
CAS
73590-58-6
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
WIKIPEDIA
OMEPRAZOLE
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
PUBCHEM
4594
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
USP_CATALOG
1478505
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY USP-RS
EPA CompTox
73590-58-6
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
DRUG BANK
DB00338
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
FDA UNII
KG60484QX9
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
HSDB
3575
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
EVMPD
SUB09439MIG
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
ChEMBL
CHEMBL1503
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
IUPHAR
4279
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
LACTMED
Omeprazole
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
DRUG CENTRAL
1990
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
INN
5081
Created by admin on Fri Jun 25 21:00:46 UTC 2021 , Edited by admin on Fri Jun 25 21:00:46 UTC 2021
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> INHIBITOR
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
TARGET -> INHIBITOR
METABOLIC ENZYME -> INDUCER
METABOLIC ENZYME -> INDUCER
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
BINDER->LIGAND
BINDING
TRANSPORTER -> INHIBITOR
METABOLIC ENZYME -> INHIBITOR
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> INDUCER
ENANTIOMER -> RACEMATE
Related Record Type Details
METABOLITE INACTIVE -> PARENT
SUBSTRATE
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE INACTIVE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
Impurities F and G: maximum 350 ppm for the sum of the contents
EP
IMPURITY -> PARENT
Impurities F and G: maximum 350 ppm for the sum of the contents
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Hepatic Imairment
PHARMACOKINETIC